Distinct cerebrospinal fluid amyloid‐beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia
暂无分享,去创建一个
G. Frisoni | S. Galluzzi | G. Amicucci | C. Geroldi | G. Binetti | A. Prestia | L. Benussi | R. Ghidoni | Anna Paterlini | Valentina Albertini | M. Glionna | L. Bocchio-Chiavetto | A. Adorni | Michela Glionna
[1] K. Blennow,et al. Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment. , 2011, Current pharmaceutical design.
[2] P. Thompson,et al. Alzheimer's CSF markers in older schizophrenia patients , 2011, International journal of geriatric psychiatry.
[3] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[4] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[5] Huaxi Xu,et al. APP processing in Alzheimer's disease , 2011, Molecular Brain.
[6] Simone Lista,et al. Optimization protocol for amyloid‐β peptides detection in human cerebrospinal fluid using SELDI TOF MS , 2010, Proteomics. Clinical applications.
[7] P. Thompson,et al. In Vivo Neuropathology of Cortical Changes in Elderly Persons with Schizophrenia , 2009, Biological Psychiatry.
[8] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[9] R. Nitsch,et al. Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology , 2004, Neurodegenerative Diseases.
[10] P. Lewczuk,et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide , 2003 .
[11] A. Delacourte,et al. Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.
[12] V. Haroutunian,et al. Amyloid β Pathology in Alzheimer’s Disease and Schizophrenia , 2003 .
[13] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[14] J. Kornhuber,et al. Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.
[15] K. Blennow,et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.
[16] E. Susser,et al. Senile degeneration and cognitive impairment in chronic schizophrenia. , 1998, The American journal of psychiatry.
[17] D. Selkoe,et al. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .
[18] J. Trojanowski,et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. , 1998, Archives of general psychiatry.
[19] K. Davis,et al. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. , 1998, Archives of general psychiatry.
[20] M. Tabaton,et al. Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains , 1997, FEBS letters.
[21] J. Trojanowski,et al. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. , 1996, The American journal of pathology.
[22] Jane S. Paulsen,et al. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. , 1994, Archives of General Psychiatry.
[23] J. Kleinman,et al. A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia , 1993, Psychiatry Research.
[24] D. Selkoe,et al. Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.
[25] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[26] P. Rossini,et al. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. , 2009, Journal of Alzheimer's disease : JAD.